The primary therapeutic role of this combined preparation may be relevant for easing symptoms related to specific prostate conditions and may assist with easing the associated painful and inflammatory symptoms. In terms of the active antimicrobial component, the medicine is applied in therapeutic domains involving bacterial infection or is used in clinical settings for supportive prophylaxis.

The medication is relevant for easing symptoms in conditions such as Chronic Bacterial Prostatitis (CBP) and localized pain and urinary distress (e.g., dysuria). It may be applied in scenarios where symptomatic support is needed, including the context of infectious complications following urological surgery (e.g., TURP). This therapeutic strategy helps address symptom clusters related to physical discomfort and conditions characterized by recurrent or episodic manifestations.

This medication provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

This approach is considered relevant for managing symptoms that create noticeable functional strain. By addressing the symptoms related to infection and inflammation, the preparation helps patients cope more steadily with symptom fluctuations.

---

Quick Fact: Symptomatic support for Localized Pain and Urinary Distress

Eligibility Map: Who Can and Cannot Use Vitaprost Plus

The official population eligibility is based on regulatory constraints associated with the Lomefloxacin component, a quinolone antimicrobial.

---

Eligibility Scope

Classification	Population/Condition
Contraindicated	Individuals with known hypersensitivity to any quinolone antibacterial agent. Patients with a history of Myasthenia Gravis.
Not Recommended	Pediatric and adolescent patients (under 18 years). Use is not recommended during pregnancy due to the risk of fetal harm.
Restricted Use	Patients with severe renal impairment (Creatinine Clearance le 40 mL/min) require mandatory dose adjustment. Use is prohibited for individuals with a history of tendon disorders or QT interval prolongation.

Age-Related and Conditional Rules

Age-related eligibility rules: The medicine is restricted to adults 18 years of age and older. Geriatric patients (ge 60 years) require special consideration due to an officially noted increased risk for tendon disorders and QT interval changes.

Eligibility-related restrictions: Caution is required when the medicine is administered to a nursing woman. Furthermore, use must be approached with caution when administered concurrently with corticosteroids, as this increases the risk of tendon rupture.

---

Connection to the Overall Eligibility Profile

Official regulatory documents define the eligible patient population as primarily Adult Male Patients without specific contraindicating conditions. The constraints establish absolute exclusions (contraindications) and define conditional use required for patients with specific age, organ function, or medical history limitations, which govern who can and cannot use the medicine.

Interactions with other medicines and products

Official regulatory documentation identifies specific interaction patterns involving the Lomefloxacin component of this combination product. The prostate extract component has no formally documented interactions in regulatory labeling.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type	Interacting Substance/Category	Official Interaction Outcome
Absorption Interference	Multivalent Cation-Containing Products (e.g., antacids, iron supplements, sucralfate)	Decreases Lomefloxacin absorption, reducing systemic exposure.
Metabolic Inhibition	Theophylline (or Aminophylline)	Decreases the metabolism of Theophylline, increasing its serum concentration and systemic exposure.
Pharmacodynamic Risk	Class IA and Class III Antiarrhythmics	Increases the risk of QTc interval prolongation due to an additive effect.
CNS Effect	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)	May increase the neuroexcitatory activities of Lomefloxacin.

---

Administration and Contextual Restrictions

The label mandates that multivalent cation-containing products must be administered separated by at least 2 hours from Lomefloxacin to prevent the documented reduction in absorption. Co-administration with food also delays the rate and slightly reduces the extent of Lomefloxacin absorption. Additionally, official documents state that concomitant use with Class IA and Class III Antiarrhythmics should be avoided due to significant risk. The pharmacokinetic profile in patients with hepatic impairment (cirrhosis) does not necessitate dosage adjustments, provided renal function is adequate.

Inhibition of Bacterial Genetic Function

This domain is driven by the synthetic component, Lomefloxacin, which exerts a bactericidal effect by acting as a highly selective inhibitor of two essential bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. This targeted molecular blockade prevents the bacteria from replicating or repairing its DNA, leading to a rapid cessation of microbial proliferation and the resulting biological consequence of reducing the microbial population.

---

Modulation of Inflammatory and Vascular Dynamics

The second core domain is governed by the peptide-based Prostate Extract, an organotropic agent. This component engages mechanisms that modulate local inflammatory signaling by regulating the release of key pro-inflammatory mediators. It also influences the local microvasculature, decreasing capillary permeability and fluid leakage. This action results in a decrease of tissue fluid accumulation and supports the regulation of microcirculatory dynamics within the affected area.

---

Synergy of Dual Mechanistic Pathways

The overall mechanistic profile arises from the complementary synergy of these two distinct mechanisms. The drug simultaneously removes the microbial population via DNA inhibition while addressing the resulting physiological state of increased inflammation and circulatory disturbances, supporting local tissue regulation.

Official Administration Protocol

Vitaprost Plus is a combined pharmaceutical preparation administered exclusively via the rectal route due to its formulation as a suppository. This method is specifically designated to facilitate targeted, local delivery of the active components: Lomefloxacin (100 mg) and Prostate Extract (50 mg). The specific usage guidelines, including dosing and administration context, are outlined for the medication.

---

Dosage, Frequency, and Duration

Instruction	Detail
Route of administration	Rectal use only; the suppository is not for oral ingestion.
Standard Dosing	One (1) suppository per administration.
Frequency	Once daily.
Duration	The standard course of therapy is typically defined as 10 days, though extended courses may be utilized for certain chronic conditions.

---

Procedural and Contextual Instructions

The official instructions mandate specific timing and preparation to ensure optimal use. The suppository is typically administered at bedtime to promote optimal drug retention and local activity. A crucial procedural condition is the recommendation to use the medication following a bowel movement to help ensure the dose is retained. The preparation is designated for use in adult male patients. High-level dose adjustments for the local suppository based on organ impairment are generally not specified in primary instructions, but the drug is intended for use as a whole unit.

Research evidence / Overview of studies for Vitaprost Plus

Research Evidence for Chronic Bacterial Prostatitis (CBP)

Clinical research has focused on the use of Vitaprost Plus in adult male patients diagnosed with Chronic Bacterial Prostatitis (CBP), a condition characterized by fluctuating or episodic manifestations. The core evidence structure includes Randomized Controlled Trials (RCTs) and comparative clinical studies. Research explored outcomes monitoring patient-reported physical discomfort and systemic imbalance. Studies also monitored objective outcomes, such as microbiological markers related to pathogen status and signs of local inflammatory states.

Research describes patterns observed in the studies, particularly concerning how symptoms evolved over the defined time intervals. However, the evidence is derived primarily from short-term trials. Follow-up durations were limited, typically only tracking observed responses up to about one month after the treatment course ended. Comparative evidence against placebo is limited in some trials. Therefore, long-term effects on symptom stability and durability of response are not fully established.

Research Structure for Surgical Prophylaxis

Vitaprost Plus was studied for its administration in research exploring short-term symptom changes related to the clinical context of infectious-inflammatory complications following urological surgical procedures, such as Transurethral Resection of the Prostate (TURP). These studies were conducted as RCTs focusing on adult male surgical patients.

Studies monitored the incidence rate of infectious and inflammatory issues as the primary outcome. Observations were confined to the immediate post-operative period, typically assessing patient status up to ten days following the procedure. The research supporting this application remains small in scale and is considered to have a low level of evidence. The results apply only to the populations studied—those undergoing a specific type of prostate surgery—and sample sizes were modest.

Key Limitations and Areas of Research Uncertainty

The research base highlights several research limitation frames. Follow-up durations were limited for the primary indication of CBP. While the combination product was evaluated in comparative settings, comparative evidence is limited against other established treatments. Furthermore, the overall certainty of the evidence remains low to moderate across the two main studied indications. The available studies help show what has been observed so far, rather than providing definitive conclusions across all patient types or timeframes.

Key Studies & References

1. European Association of Urology Guidelines on Chronic Pelvic Pain (2025 Full Text)

Common questions about Vitaprost Plus (FAQ)

Q: Is Vitaprost Plus a prostate infection treatment or just for inflammation?

According to the official product information, Vitaprost Plus is a combination medicine. It contains a quinolone antimicrobial agent (Lomefloxacin) to help address bacterial infection, and an organotropic agent (Prostate Extract) that is intended to help reduce inflammation and local tissue swelling. Therefore, its design is intended to address both components of the condition.

Q: What happens if I miss a dose of Vitaprost Plus?

Regulatory language typically states that if a dose is missed, it should be administered as soon as it is remembered. Official instructions advise that if it is almost time for the next scheduled dose, the missed dose is skipped to continue the regular schedule. Patients are instructed not to administer a double dose to compensate for a missed one.

Q: Is it okay to use Vitaprost Plus if I have a history of allergies?

Official regulatory documents indicate that this medicine is strictly contraindicated if a patient has a known hypersensitivity (a severe allergic reaction) to any quinolone antibacterial agent or to the Prostate Extract component. A history of allergies warrants discussion with a healthcare provider before initiating this medication.

Q: What does the 'Plus' in Vitaprost Plus refer to?

The 'Plus' refers to its unique, dual-action formula. The formulation combines the Lomefloxacin component, which is a quinolone antimicrobial, with the Prostate Extract component, which acts as an organotropic agent. This specific combination is what distinguishes the formulation.

Q: Has Vitaprost Plus been tested on younger men for prostate concerns?

Official regulatory documents state that this medicine is restricted to adults 18 years of age and older. Use in children and adolescent patients (under 18 years) is generally not recommended due to safety considerations associated with the antimicrobial component.

Q: Are there any vitamins or supplements that interact with Vitaprost Plus?

The Lomefloxacin component, which is a quinolone, can interact with supplements containing multivalent cations such as iron, magnesium, or zinc. These are common ingredients in multivitamins and certain mineral supplements. Regulatory documents typically mandate a separation of dosing times (usually at least two hours) to prevent documented reduction in drug absorption.

Q: Does Vitaprost Plus interact with medications for erectile dysfunction?

While there is no universally documented direct interaction between the active components and all erectile dysfunction (ED) medications, the quinolone component is associated with a risk of QTc interval prolongation (a change in heart rhythm). The potential interaction should be reviewed by a healthcare provider, especially when using other medications that may affect heart rhythm.

Q: Is there a specific time of day best for using Vitaprost Plus?

Yes. Official instructions state that the suppository is typically administered at bedtime. This specific timing is recommended in regulatory documents to help promote optimal retention of the medicine and facilitate its intended local activity.

Q: Can Vitaprost Plus cause drowsiness or affect the ability to drive?

Official safety documents list common adverse reactions, including effects on the nervous system such as headache and dizziness. Due to these potential effects, caution is warranted when performing activities that require full mental alertness, such as driving or operating heavy machinery.

Q: Where does the active substance in Vitaprost Plus come from?

Vitaprost Plus has a dual origin. The active substance Lomefloxacin is a manufactured synthetic component, acting as the antimicrobial agent. The Prostate Extract component, on the other hand, is a peptide preparation derived from natural sources, which acts to support the prostate tissue.

Q: Is the absorption rate of Vitaprost Plus different from other forms of medication?

Yes, it is formulated as a rectal suppository specifically to facilitate the targeted, local delivery of the active components to the affected area. This local mechanism of action is distinct from systemic forms of medication, such as oral tablets, which are designed primarily for full-body absorption.

How to Store and Dispose of Vitaprost Plus?

The storage and disposal of Vitaprost Plus (rectal suppositories) are governed by official regulatory instructions to maintain product stability and ensure safe handling.

---

Official Storage Requirements

Condition	Regulatory Requirement
Temperature	Must be stored at a temperature not exceeding 25 C (or 20 C in certain regional forms).
Protection	Must be kept in the original contour cellular packaging (blister) and protected from light.
Child Safety	Must be stored out of the sight and reach of children.

---

Disposal Instructions

• Unused Product: Expired or unused suppositories must be disposed of according to local regulations for pharmaceutical waste.
• Environmental Restriction: The medicine must not be discarded via wastewater (e.g., flushed down the toilet) or household trash, which is a requirement due to the presence of the antimicrobial component.